CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.


Begin main content

Call for Patient Input and Clinical Experts: Mayzent and brolucizumab

Published on: August 28, 2019
Result type: News

CADTH has received the following notice(s) of pending drug submission(s).

Brand name Mayzent TBC
Generic name siponimod brolucizumab
Manufacturer Novartis Pharmaceuticals Canada Inc. Novartis Pharmaceuticals Canada Inc.
Indication(s) For the treatment of patient with secondary progressive multiple sclerosis. Macular degeneration, age-related
Project Number SR0630-000 SR0631-000
Call for patient input 2019-08-28 2019-08-28
Patient input deadline 2019-10-18 2019-10-18
Submit patient input Submit Submit
Register as Clinical Expert Register Register